The global T-cell therapy market size is calculated at USD 7.59 billion in 2024, grew to USD 10.30 billion in 2025, and is predicted to hit around USD 161.21 billion by 2034, poised to grow at a CAGR of 35.74% between 2024 and 2034. The North America T-cell therapy market size accounted for USD 4.86 billion in 2024 and is anticipated to grow at the fastest CAGR of 35.85% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: T-cell Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. T-cell Therapy Market, by Therapy Type, 2024-2034
8.1.1 CAR T-cell Therapy
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. T Cell Receptor (TCR)-based
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Tumor Infiltrating Lymphocytes (TIL)-based
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. T-cell Therapy Market, by Indication, 2024-2034
9.1.1. Hematologic Malignancie
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Solid Tumors
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. T-cell Therapy Market, by End User, 2024-2034
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Cancer Treatment Centers
10.1.2.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Indication (2021-2034)
11.1.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Indication (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Indication (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Indication (2021-2034)
11.2.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Indication (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Indication (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Indication (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Indication (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Indication (2021-2034)
11.3.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Indication (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Indication (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Indication (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Indication (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Indication (2021-2034)
11.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Indication (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Indication (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Indication (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Indication (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Indication (2021-2034)
11.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Indication (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Indication (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End User (2021-2034)
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Fate Therapeutics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sorrento Therapeutics
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. TCR2 Therapeutics Inc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bluebird Bio Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Gilead Sciences Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck KGaA
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Novartis AG
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Amgen
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Celgene Corporation
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample